Head-to-head evidence
Alimatravir vs Dapivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Alimatravir
Developed by Merck & Co.
NCT06045507 · Phase 2 · completed
The study randomized 352 participants to three MK-8527 dose groups or matched placebo and used double blinding, but Alimatravir was not studied and was not the comparator. Its primary endpoints were safety outcomes rather than efficacy, and the registry provides counts without statistical comparisons, so whether the primary comparisons were met cannot be determined.
Next expected readout: January 2027 · NCT07600775 (registry estimate)
Dapivirine · Dapivirine Vaginal Ring
Marketed by International Partnership for Microbicides
NCT01617096 · Phase 3 · completed
This Phase 3 trial randomized 2,629 women to a monthly dapivirine vaginal ring or a placebo ring, with both participants and investigators blinded. The primary endpoint was HIV-1 seroconversion, and the results show 71 seroconversions among 1,313 women in the dapivirine group versus 97 among 1,313 in the placebo group; however, no p-value or confidence interval is provided in the registry, so it is uncertain whether this difference was statistically significant. Because the design is robust but the primary comparison's significance is not established, the evidence is moderate rather than strong.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alimatravir's landscape · Dapivirine's landscape